Regional nodal irradiation after neoadjuvant therapy
Ask about this lessonIn one sentence
Regional nodal irradiation treats the lymph-node regions that drain the breast, and after neoadjuvant therapy the question is whether the nodes' response to treatment changes who needs it.
The intuition
Think of the armpit nodes as a checkpoint downstream of the breast. Before treatment, a biopsy shows cancer reached the checkpoint. After treatment given before surgery (neoadjuvant therapy), surgery shows whether cancer is still there. Radiation to the node regions is insurance against cancer cells nobody can see. The question is whether a clean checkpoint after treatment means the insurance is no longer worth its cost. The analogy breaks because a clean sample covers only the nodes removed, not every node in the region.
How it works
Regional nodal irradiation (RNI) adds radiation fields beyond the breast or chest wall. Depending on the plan, fields can include the axillary (armpit) levels, the nodes above the collarbone (supraclavicular) and the internal mammary nodes beside the breastbone. The lymphatic drainage map shows where these regions sit.
After neoadjuvant therapy, the surgical node result is written with a "y" prefix. ypN0 means no cancer was found in the nodes examined after treatment; ypN+ means cancer remained. See N categories. The node result comes from sentinel-node biopsy, targeted dissection or axillary dissection, so how many nodes were examined matters.
Two randomized trials split the question by that result:
| Trial | Who entered | Comparison | Result |
|---|---|---|---|
| NSABP B-51 / NRG Oncology RTOG 1304 | Clinical T1–3, biopsy-proven N1 breast cancer that became ypN0 after neoadjuvant chemotherapy; 1,556 analyzed | Regional nodal irradiation versus none | No significant difference in the invasive breast cancer recurrence-free interval: hazard ratio 0.88 (95% confidence interval 0.60–1.28; P = 0.51), point estimates free of primary events 92.7% versus 91.8%; median follow-up 59.5 months |
| Alliance A011202 | Clinical T1–3 N1 breast cancer with a sentinel node still positive after neoadjuvant chemotherapy; 2,012 enrolled | Completion axillary dissection plus nodal radiation versus axillary plus nodal radiation without dissection | Not yet reported; the registry lists primary completion in 2031 |
In B-51, everyone treated with lumpectomy received whole-breast radiation, with or without the nodal fields; after mastectomy, the comparison was chest-wall plus nodal radiation versus no radiation. B-51 also found no improvement in local-regional recurrence, distant recurrence, disease-free survival or overall survival. Grade 4 adverse events occurred in 0.5% with radiation and 0.1% without.
Why it matters in cancer
- For people whose nodes became ypN0, B-51 gives randomized evidence that regional nodal irradiation may be omitted without a measurable recurrence penalty at about five years.
- For people with remaining node disease, regional radiation is still given in both arms of A011202; that trial asks whether surgery or radiation should treat the armpit, not whether to skip nodal treatment.
- Omitting a field removes its normal-tissue exposure. The National Cancer Institute (NCI) lists lymphedema (arm swelling) and heart and lung problems among possible late effects of breast radiation.
Common confusions
- ypN0 versus pathologic complete response. ypN0 describes the nodes only. Pathologic complete response also requires no invasive cancer in the breast.
- "No benefit shown" versus "proven harmless to omit." B-51's confidence interval, 0.60 to 1.28, still allows a modest effect in either direction, and later recurrences need longer follow-up.
- Breast radiation versus nodal radiation. After lumpectomy, B-51 tested only the nodal fields; whole-breast radiation was given in both arms.
- One trial's population. B-51 enrolled clinical N1 disease (one to three nodes) proven by biopsy. It does not directly answer the question for more extensive nodal disease (N2–N3) before treatment.
How it is measured
The outcome is a time-to-event endpoint; see survival endpoints and hazard ratio. The B-51 primary endpoint counted invasive breast cancer recurrence or death from breast cancer. Normal-tissue effects are recorded separately by grade.
Worked example
Fictional reader. A summary says: "B-51 proved nodal radiation is useless after chemotherapy." What is wrong?
Answer: Three things. B-51 applies to biopsy-proven N1 disease that became ypN0, not to anyone with residual node cancer. It tested regional nodal fields, not all radiation. And "no significant difference" at about five years, with a confidence interval from 0.60 to 1.28, is not proof of zero effect.
Explain it back
Fill in: "After neoadjuvant therapy, the decision about nodal radiation depends on ___ before treatment and ___ at surgery, and B-51 answered it only for ___."
One answer: nodal stage before treatment; the ypN result at surgery; biopsy-proven N1 disease that became ypN0.
Takeaway
After neoadjuvant therapy, the nodes' response changes the radiation question: B-51 found no recurrence benefit from nodal radiation when N1 nodes became ypN0, while the trial for remaining node disease has not reported.
Related concepts
Sources and scope
Source check: November 7, 2026. Concept and trial design only; no individual radiation recommendation. Expert and learner review pending.
- Mamounas et al., 2025: NSABP B-51 / NRG Oncology RTOG 1304, New England Journal of Medicine — complete abstract checked for population, comparison, endpoint, hazard ratio, point estimates and adverse events.
- ClinicalTrials.gov NCT01872975: NSABP B-51 arms — registry arm descriptions checked for lumpectomy and mastectomy groups.
- NCI: radiation for breast cancer — late effects list checked.
- ClinicalTrials.gov NCT01901094: Alliance A011202 — registry checked November 7, 2026 for eligibility, arms, enrollment, status and estimated primary completion.